Escherichia coli and Colorectal Cancer: Unfolding the Enigmatic Relationship

Curr Pharm Biotechnol. 2022;23(10):1257-1268. doi: 10.2174/1389201022666210910094827.

Abstract

Colorectal cancer (CRC) is one of the deadliest cancers in the world. Specific strains of intestinal Escherichia coli (E. coli) may influence the initiation and development of CRC by exploiting virulence factors and inflammatory pathways. Mucosa-associated E. coli strains are more prevalent in CRC biopsies in comparison to healthy controls. Moreover, these strains can survive and replicate within macrophages and induce a pro-inflammatory response. Chronic exposure to inflammatory mediators can lead to increased cell proliferation and cancer. Production of colobactin toxin by the majority of mucosa-associated E. coli isolated from CRC patients is another notable finding. Colibactin-producing E. coli strains, in particular, induce double-strand DNA breaks, stop the cell cycle, involve in chromosomal rearrangements of mammalian cells and are implicated in carcinogenic effects in animal models. Moreover, some enteropathogenic E. coli (EPEC) strains are able to survive and replicate in colon cells as chronic intracellular pathogens and may promote susceptibility to CRC by downregulation of DNA Mismatch Repair (MMR) proteins. In this review, we discuss current evidence and focus on the mechanisms by which E. coli can influence the development of CRC.

Keywords: DNA mismatch repair; E. coli; colibactin; colorectal cancer; cyclomodelin; inflammation.

Publication types

  • Review

MeSH terms

  • Animals
  • Colorectal Neoplasms* / genetics
  • Down-Regulation
  • Escherichia coli / metabolism
  • Escherichia coli Infections*
  • Humans
  • Mammals